Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.
Abstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
In one paragraph
Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Trial
- Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost.Nature communications · 2025Trial
- Variant-specific antibody correlates of protection against SARS-CoV-2 Omicron symptomatic and overall infections.Nature communications · 2025Article
- Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
44 authors.
Youyi FongVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Lauren DangBiostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Bo ZhangVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Jonathan FintziBiostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Shiyu ChenVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Jing WangFrederick National Laboratory for Cancer Research, Clinical Monitoring Research Program Directorate, Frederick, Maryland, USA.
Nadine G RouphaelHope Clinic, Department of Medicine, Division of Infectious Diseases, Emory University, Decatur, Georgia, USA.
Angela R BrancheVaccine and Treatment Evaluation Unit, University of Rochester, Rochester, New York, USA.
David J DiemertGeorge Washington Vaccine Research Unit, George Washington University, Washington, District of Columbia, USA.
Ann R FalseyVaccine and Treatment Evaluation Unit, University of Rochester, Rochester, New York, USA.
Cecilia LosadaHope Clinic, Department of Medicine, Division of Infectious Diseases, Emory University, Decatur, Georgia, USA.
Lindsey R BadenDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Sharon E FreyCenter for Vaccine Development, Saint Louis University, Saint Louis, Missouri, USA.
Jennifer A WhitakerDepartment of Molecular Virology and Microbiology and Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Susan J LittleDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla, California, USA.
Satoshi KamidaniCenter for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Emmanuel B WalterDuke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Richard M NovakProject WISH, University of Illinois at Chicago, Chicago, Illinois, USA.
Richard RuppDepartment of Pediatrics, University of Texas Medical Branch, Galveston, Texas, USA.
Lisa A JacksonDepartment of Internal Medicine, Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.
Chenchen YuVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Craig A MagaretVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Cindy MolitorVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Bhavesh BorateVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Tara M BabuDivision of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.
Angelica C KottkampVaccine and Treatment Evaluation Unit, Manhattan Research Clinic, New York University Grossman School of Medicine, New York, New York, USA.
Anne F LuetkemeyerDivision of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, California, USA.
Lilly C ImmergluckClinical Research Center, Department of Microbiology, Biochemistry, and Immunology, Morehouse School of Medicine, Atlanta, Georgia, USA.
Rachel M PrestiDepartment of Medicine, Washington University School of Medicine, St Louis, Missouri, USA.
Martín BäckerVaccine and Treatment Evaluation Unit, Long Island Research Clinic, New York University, Long Island School of Medicine, Mineola, New York, USA.
Patricia L WinokurDepartment of Medicine, University of Iowa College of Medicine, Iowa City, Iowa, USA.
Siham M MahgoubHoward University College of Medicine, Howard University Hospital, Washington, District of Columbia, USA.
Paul A GoepfertDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Dahlene N FuscoDepartment of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Robert L AtmarDepartment of Molecular Virology and Microbiology and Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Christine M PosavadInfectious Diseases Clinical Research Consortium (IDCRC) Laboratory Operations Unit, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Jinjian MuDepartment of Biostatistics, The Emes Company, LLC, Rockville, Maryland, USA.
Mat MakowskiDepartment of Biostatistics, The Emes Company, LLC, Rockville, Maryland, USA.
Mamodikoe K MakheneDivision of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Seema U NayakDivision of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Paul C RobertsDivision of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Dean FollmannBiostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Peter B GilbertVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0002-2662-9427
Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team
Funding
LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6MLC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6MSDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9MStatistical Data Coordinating Center: Monkeypox Clinical Research Support75N93021C00012 · NIAID · THE EMMES COMPANY, LLC · PI EWELL, MARIAN · 2021 to 2025
$150.3MLeadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) - Momi-Vax DMID #21-0004 {Supplement #6}UM1AI148684 · NIAID · EMORY UNIVERSITY · PI DAVID S STEPHENS · 2020 to 2026
$77.2MVaccine and Treatment Evaluation Unit at Saint Louis University - DMID 20-0034UM1AI148685 · NIAID · SAINT LOUIS UNIVERSITY · PI Daniel F. Hoft · 2020 to 2026
$34.6MUniversity of Washington Vaccine and Treatment Evaluation Unit - DMID 21-0012UM1AI148573 · NIAID · UNIVERSITY OF WASHINGTON · PI Raymond Scott McClelland, Anna Wald · 2020 to 2026
$26.6MStatistical Methods in HIV Vaccine Efficacy TrialsR37AI054165 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert · 2010 to 2026
$6.7MCLINICAL CENTRAL LABORATORY SERVICES TO SUPPORT COVID-19 VACCINE STUDIES75N93021D00021 · NIAID · PI BEECH, TIFFANI · 2021 to 2023
$1.6MAdministration for Strategic Preparedness and Response 75A50122C00008Biomedical Advanced Research and Development Authority 75A50122C00008BLRD VA I01 BX000207CLC NIH HHS C0000008CSRD VA I01 CX002688HHSInfectious Diseases Clinical Research Consortium UM1AI148684National Institute of Allergy and Infectious Diseases R37AI054165NCI NIH HHS 75N910D00024NIAID NIH HHS 75N93021C00012NIAID NIH HHS 75N93021D00021NIAID NIH HHS R37 AI054165NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068618NIAID NIH HHS UM1 AI068635NIAID NIH HHS UM1 AI148573NIAID NIH HHS UM1 AI148684NIAID NIH HHS UM1 AI148685NIH HHSSanofiUS Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense W15QKN-16-9-1002
Abstract
For COVAIL recipients of a coronavirus disease 2019 (COVID-19) Sanofi booster vaccine, neutralizing antibody titers were assessed as a correlate of risk (CoR) of COVID-19. Peak and exposure-proximal titers were inverse CoRs with covariate-adjusted hazard ratios (95% confidence intervals) 0.30 (0.11, 0.78) and 0.25 (0.07, 0.85) per 10-fold increase in weighted average titer.
Indexed as
Antibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 VaccinesAdultFemaleHumansImmunization, SecondaryMaleMiddle AgedSARS-CoV-2Vaccines, SyntheticAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesVaccines, Syntheticcorrelate of riskCOVID-19 boosterexposure-proximal titerOmicronvariant vaccine booster
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.